Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Genexine, Inc. (095700.KQ)
KRW2,325.00
+130.00 (+5.92%)
KR KOE Healthcare Biotechnology
Address
Korea Bio Park Building B 13488
Seongnam, KR
Seongnam, KR
CEO
Jungwon Woo
Website
genexine.com
IPO
2009-09-15
ISIN KR7095700001
Description
Genexine, Inc. is a South Korean clinical-stage biotechnology firm dedicated to advancing and commercializing immunotherapeutics and extended-duration biologics. The company leverages two key proprietary technologies: the hyFc platform, engineered for discovering diverse agonistic protein therapeutics, and an Immune Enhancing Technology, which focuses on therapeutic DNA vaccines. Its extensive pipeline features several drug candidates: GX-H9, currently in Phase II trials for treating growth hormone deficiency in both adults and children; GX-E2, also in Phase II, addressing induced anemia; GX-G3, in Phase II for neutropenia; and GX-G6, undergoing Phase I studies for diabetes. Additionally, GX-188E is in Phase II clinical trials, being evaluated in combination with KEYTRUDA for cervical cancer treatment. Genexine has also forged a co-development alliance with Binex Co. Ltd. to create a COVID-19 vaccine. Founded in 1999 as Genexine Co., Ltd., the company adopted its current name, Genexine, Inc., in March 2013 and is headquartered in Seongnam, South Korea.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
KRW2,325.00
+130.00 (+5.92%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
537.8K
Beta
0.36
Float Shares
33.87M
Free Float %
74.5%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -3.30% | -18.65% | -42.25% | -9.09% | -14.58% | -16.16% | -10.48% | -65.43% | -94.90% | -90.36% | -60.66% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
2,325.00
Ratings Trend (MoM)
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
0.10
Distress
Piotroski F-Score
2 / 9
Weak
MOAT Score
0 / 10
No MOAT
Composite Rating
C
Overall Score
2 / 5
Medium
DCF Score
1 / 5
Low
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
2 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
4 / 5
High
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%+56.0% ★ Q1'26: +29.8% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%+60.7% ★ Q1'26: +34.2% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%-785.5% Q1'26: -2,005.0% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%-788.2% Q1'26: -2,119.6% (vs Q1'25)
-
ROIC Biotechnology: -16.1%-11.3% ★ Q1'26: -11.4% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+7.8% Q1'26: +0.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-3.71× Q1'26: -3.70× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
Dec 2029 1 Rev. Ana. 1 EPS Ana. |
Dec 2030 1 Rev. Ana. 1 EPS Ana. |
Dec 2031 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
32.52B
est: 32.50B (+0.1%)
|
11.35B
est: 17.60B (-35.5%)
|
28.45B
est: 17.60B (+61.7%)
|
12.88B
est: 15.65B (-17.7%)
|
11.30B
est: 9.11B (+24.1%)
|
18.54B
est: 19.10B (-2.9%)
|
36.83B
est: 18.43B (+99.8%)
|
16.14B
est: 84.09B (-80.8%)
|
4.43B
est: 58.41B (-92.4%)
|
2.93B
est: 10.00M (+29,227.4%)
|
4.57B
est: 15.65B (-70.8%)
|
15.65B
15.65B – 15.65B
+0.0% YoY
|
9.11B
9.11B – 9.11B
-41.8% YoY
|
19.10B
19.10B – 19.10B
+109.7% YoY
|
18.43B
18.43B – 18.43B
-3.5% YoY
|
84.09B
84.09B – 84.09B
+356.2% YoY
|
58.41B
58.41B – 58.41B
-30.5% YoY
|
| EBITDA |
8.70B
est: -30.11B (+128.9%)
|
-27.65B
est: -16.31B (-69.6%)
|
-15.57B
est: -16.31B (+4.5%)
|
-29.12B
est: -14.50B (-100.8%)
|
6.56B
est: -8.44B (+177.8%)
|
-36.23B
est: -17.69B (-104.8%)
|
-23.30B
est: -17.08B (-36.4%)
|
-28.81B
est: -77.91B (+63.0%)
|
-40.88B
est: -54.12B (+24.5%)
|
-57.33B
est: -9.27M (-618,700.8%)
|
-29.04B
est: -14.50B (-100.3%)
|
-14.50B
-14.50B – -14.50B
+0.0% YoY
|
-8.44B
-8.44B – -8.44B
+41.8% YoY
|
-17.69B
-17.69B – -17.69B
-109.7% YoY
|
-17.08B
-17.08B – -17.08B
+3.5% YoY
|
-77.91B
-77.91B – -77.91B
-356.2% YoY
|
-54.12B
-54.12B – -54.12B
+30.5% YoY
|
| EBIT |
5.09B
est: -30.69B (+116.6%)
|
-30.20B
est: -16.62B (-81.7%)
|
-18.22B
est: -16.62B (-9.6%)
|
-31.40B
est: -14.78B (-112.4%)
|
-11.92B
est: -8.60B (-38.6%)
|
45.21B
est: -18.03B (+350.7%)
|
-26.60B
est: -17.41B (-52.8%)
|
-33.68B
est: -79.41B (+57.6%)
|
-45.91B
est: -55.17B (+16.8%)
|
-62.77B
est: -9.44M (-664,499.3%)
|
-36.05B
est: -14.78B (-143.9%)
|
-14.78B
-14.78B – -14.78B
+0.0% YoY
|
-8.60B
-8.60B – -8.60B
+41.8% YoY
|
-18.03B
-18.03B – -18.03B
-109.7% YoY
|
-17.41B
-17.41B – -17.41B
+3.5% YoY
|
-79.41B
-79.41B – -79.41B
-356.2% YoY
|
-55.17B
-55.17B – -55.17B
+30.5% YoY
|
| Net Income |
-1.43B
est: -2.89B (+50.7%)
|
-30.93B
est: -20.14B (-53.6%)
|
-19.33B
est: -20.14B (+4.0%)
|
-34.07B
est: -20.82B (-63.6%)
|
-16.51B
est: -41.81B (+60.5%)
|
27.57B
est: -4.08B (+775.9%)
|
-47.73B
est: -57.40B (+16.9%)
|
-55.97B
est: 26.61B (-310.3%)
|
-66.87B
est: -24.57B (-172.1%)
|
-63.71B
est: -48.47B (-31.4%)
|
-27.01B
est: -22.46B (-20.3%)
|
-22.46B
-22.46B – -22.46B
+0.0% YoY
|
-45.09B
-45.09B – -45.09B
-100.8% YoY
|
-4.40B
-4.40B – -4.40B
+90.2% YoY
|
-61.90B
-61.90B – -61.90B
-1,307.3% YoY
|
28.70B
28.70B – 28.70B
+146.4% YoY
|
-26.50B
-26.50B – -26.50B
-192.3% YoY
|
| SGA |
17.42B
est: 33.63B (-48.2%)
|
15.86B
est: 18.21B (-12.9%)
|
8.84B
est: 18.21B (-51.5%)
|
10.14B
est: 16.20B (-37.4%)
|
4.04B
est: 9.42B (-57.2%)
|
8.00B
est: 19.76B (-59.5%)
|
10.14B
est: 19.08B (-46.8%)
|
15.91B
est: 87.02B (-81.7%)
|
7.25B
est: 60.45B (-88.0%)
|
5.41B
est: 11.17M (+48,332.7%)
|
3.85B
est: 17.48B (-78.0%)
|
17.48B
17.48B – 17.48B
+0.0% YoY
|
10.17B
10.17B – 10.17B
-41.8% YoY
|
21.33B
21.33B – 21.33B
+109.7% YoY
|
20.59B
20.59B – 20.59B
-3.5% YoY
|
93.93B
93.93B – 93.93B
+356.2% YoY
|
65.25B
65.25B – 65.25B
-30.5% YoY
|
| EPS |
-61.21
est: -68.61 (+10.8%)
|
-1,379.79
est: -477.76 (-188.8%)
|
-754.73
est: -477.76 (-58.0%)
|
-1,203.58
est: -493.93 (-143.7%)
|
-556.06
est: -991.69 (+43.9%)
|
825.46
est: -96.75 (+953.2%)
|
-1,375.57
est: -1,361.45 (-1.0%)
|
-1,319.14
est: 631.24 (-309.0%)
|
-1,652.14
est: -582.83 (-183.5%)
|
-1,510.97
est: -1,066.01 (-41.7%)
|
-594.10
est: -493.93 (-20.3%)
|
-493.93
-493.93 – -493.93
+0.0% YoY
|
-991.69
-991.69 – -991.69
-100.8% YoY
|
-96.75
-96.75 – -96.75
+90.2% YoY
|
-1,361.45
-1,361.45 – -1,361.45
-1,307.3% YoY
|
631.24
631.24 – 631.24
+146.4% YoY
|
-582.83
-582.83 – -582.83
-192.3% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-19 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-18 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-15 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-14 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-13 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-12 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-11 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-08 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-07 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-06 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-04 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-30 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-29 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-28 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-27 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-24 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-23 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-22 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-21 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-20 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-17 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-16 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-23.43B
OE per share TTM
-515.06
Owner's Yield
-12.15%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
749.0%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 23 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Vanguard FTSE All-World ex-US Small-Cap ETF VSS | 0.00% | 438.6K | 0.06% |
| 2 | Vanguard FTSE Developed Asia Pacific All Cap Index ETF VA.TO | 0.00% | 2.5K | 0.22% |
| 3 | Vanguard FTSE Pacific ETF VPL | 0.00% | 94.1K | 0.07% |
| 4 | Avantis Emerging Markets Small Cap Equity ETF AVEE | 0.00% | 413.24 | 0.42% |
| 5 | Vanguard FTSE Developed All Cap ex U.S. Index ETF VDU.TO | 0.00% | 1.7K | 0.22% |
| 6 | Vanguard FTSE Developed All Cap ex U.S. Index ETF (CAD-hedged) VEF.TO | 0.00% | 2.7K | 0.22% |
| 7 | Vanguard FTSE Developed All Cap ex North America Index ETF VIU.TO | 0.00% | 22.4K | 0.23% |
| 8 | Vanguard FTSE Developed All Cap ex North America Index ETF (CAD-hedged) VI.TO | 0.00% | 1.9K | 0.22% |
| 9 | Vanguard FTSE Developed Markets ETF VEA | 0.00% | 904.1K | 0.03% |
| 10 | Vanguard ESG International Stock ETF VSGX | 0.00% | 15.1K | 0.10% |
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
-4.19M
Shares Outstanding
45.48M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Chul Jun Hyun | Auditor & Director | — | — |
| Hyun Jin Park | EVP of Corporate Development | — | — |
| Jaehyun Choi | Head of R&D | — | — |
| Jang Hee Lee | EVP of Operations | — | — |
| Jong Sup Park | Chief Medical Officer | — | — |
| Jongsoo Lee | Senior Manager of IR & PR | — | — |
| Jungwon Woo | President & Director | — | — |
| Ki Yong Kim | SVP of Bio Research Institute | — | — |
| Neil K. Warma | President & Director | — | male |
| Sung-June Hong | Executive Vice President, Chief Financial Officer & Director | — | male |
| Young-Chul Sung | Founder & Chairman of the Scientific Advisory Board | — | — |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 095700.KQ
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
